Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Camelia Dumitras"'
Autor:
Junhui Hu, Ping Tan, Moe Ishihara, Nicholas A. Bayley, Shiruyeh Schokrpur, Jeremy G. Reynoso, Yangjun Zhang, Raymond J. Lim, Camelia Dumitras, Lu Yang, Steven M. Dubinett, Parmjit S. Jat, Jacques Van Snick, Jiaoti Huang, Arnold I. Chin, Robert M. Prins, Thomas G. Graeber, Hua Xu, Lily Wu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-16 (2023)
Abstract Loss of function of the von Hippel-Lindau (VHL) tumor suppressor gene is a hallmark of clear cell renal cell carcinoma (ccRCC). The importance of heterogeneity in the loss of this tumor suppressor has been under reported. To study the impact
Externí odkaz:
https://doaj.org/article/7fbb896806994806aeb3daa83568734f
Autor:
Bin Liu, Rui Li, Edward B Garon, Steven M Dubinett, Kostyantyn Krysan, Tianhao Zhang, Aaron E Lisberg, Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 9 (2023)
Background Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to p
Externí odkaz:
https://doaj.org/article/bf2a559715ab4836a9534c935ea67e88
Autor:
Sixue Liu, Hannah M. Knochelmann, Shirley H. Lomeli, Aayoung Hong, Mary Richardson, Zhentao Yang, Raymond J. Lim, Yan Wang, Camelia Dumitras, Kostyantyn Krysan, Cynthia Timmers, Martin J. Romeo, Carsten Krieg, Elizabeth C. O’Quinn, Joshua D. Horton, Steve M. Dubinett, Chrystal M. Paulos, David M. Neskey, Roger S. Lo
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 10, Pp 100411- (2021)
Summary: Neoadjuvant PD-1 blockade may be efficacious in some individuals with high-risk, resectable oral cavity head and neck cancer. To explore correlates of response patterns to neoadjuvant nivolumab treatment and post-surgical recurrences, we ana
Externí odkaz:
https://doaj.org/article/39a1c3a08dca431b9aeaf1eb80b12cdf
Autor:
Jie-Xian Dong, Yongam Lee, Michael Kirmiz, Stephanie Palacio, Camelia Dumitras, Claudia M Moreno, Richard Sando, L Fernando Santana, Thomas C Südhof, Belvin Gong, Karl D Murray, James S Trimmer
Publikováno v:
eLife, Vol 8 (2019)
Nanobodies (nAbs) are small, minimal antibodies that have distinct attributes that make them uniquely suited for certain biomedical research, diagnostic and therapeutic applications. Prominent uses include as intracellular antibodies or intrabodies t
Externí odkaz:
https://doaj.org/article/13ea854aadef4d35bafff7c930066b21
Autor:
Nicolas P Andrews, Justin X Boeckman, Colleen F Manning, Joe T Nguyen, Hannah Bechtold, Camelia Dumitras, Belvin Gong, Kimberly Nguyen, Deborah van der List, Karl D Murray, JoAnne Engebrecht, James S Trimmer
Publikováno v:
eLife, Vol 8 (2019)
Generating recombinant monoclonal antibodies (R-mAbs) from mAb-producing hybridomas offers numerous advantages that increase the effectiveness, reproducibility, and transparent reporting of research. We report here the generation of a novel resource
Externí odkaz:
https://doaj.org/article/59976df2d6b046219b7ee9969a2fedc2
Autor:
Sixue Liu, Prashanthi Dharanipragada, Shirley H. Lomeli, Yan Wang, Xiao Zhang, Zhentao Yang, Raymond J. Lim, Camelia Dumitras, Philip O. Scumpia, Steve M. Dubinett, Gatien Moriceau, Douglas B. Johnson, Stergios J. Moschos, Roger S. Lo
Publikováno v:
Nature medicine, vol 29, iss 5
Metastasis and failure of present-day therapies represent the most common causes of mortality in patients with cutaneous melanoma. To identify the underlying genetic and transcriptomic landscapes, in this study we analyzed multi-organ metastases and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5318bf99218234a1a5a9d8f3309df644
https://escholarship.org/uc/item/62m629hn
https://escholarship.org/uc/item/62m629hn
Autor:
Steven M. Dubinett, Bin Liu, Linh M. Tran, David B. Shackelford, Kostyantyn Krysan, Stacy J. Park, Zhe Jing, Camelia Dumitras, Jensen Abascal, Tianhao Zhang, Zi Ling Huang, Stephanie L. Ong, Raymond J. Lim, Milica Momcilovic, William Crosson, Ramin Salehi-Rad, Rui Li
Gene-Specific Primers and Flow Antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb25a239f92343f7791ddd75a6b9e7f
https://doi.org/10.1158/0008-5472.22429215
https://doi.org/10.1158/0008-5472.22429215
Autor:
Steven M. Dubinett, Bin Liu, Linh M. Tran, David B. Shackelford, Kostyantyn Krysan, Stacy J. Park, Zhe Jing, Camelia Dumitras, Jensen Abascal, Tianhao Zhang, Zi Ling Huang, Stephanie L. Ong, Raymond J. Lim, Milica Momcilovic, William Crosson, Ramin Salehi-Rad, Rui Li
Supplemental Figures S1-S6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b1a6c3e6608e67ea6eb1b913a81e365
https://doi.org/10.1158/0008-5472.22429218
https://doi.org/10.1158/0008-5472.22429218
Autor:
Steven M. Dubinett, Bin Liu, Linh M. Tran, David B. Shackelford, Kostyantyn Krysan, Stacy J. Park, Zhe Jing, Camelia Dumitras, Jensen Abascal, Tianhao Zhang, Zi Ling Huang, Stephanie L. Ong, Raymond J. Lim, Milica Momcilovic, William Crosson, Ramin Salehi-Rad, Rui Li
LKB1 inactivating mutations are commonly observed in patients with KRAS-mutant non–small cell lung cancer (NSCLC). Although treatment of NSCLC with immune checkpoint inhibitors (ICI) has resulted in improved overall survival in a subset of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92a10b2302ae70ae96438565171e6f5f
https://doi.org/10.1158/0008-5472.c.6513285.v1
https://doi.org/10.1158/0008-5472.c.6513285.v1
Autor:
William P. Crosson, Rui Li, Ramin Salehi-Rad, Raymond J. Lim, Jensen Abascal, Bitta P. Kahangi, Edgar Perez Reyes, Michael Oh, Camelia Dumitras, Nico Edgar, Ryan Chew, Rashel Jacobo, Zhe Jing, Kostyantyn Krysan, Linh M. Tran, Steven Dubinett, Bin Liu
Publikováno v:
Cancer Research. 83:5157-5157
Lung cancer remains the deadliest form of cancer, claiming the lives of 1.8 million individuals worldwide in 2020. While treatment options have improved with the advent of immune checkpoint inhibitors (ICI), many patients do not respond to immunother